Figure1: The picture depicted the spherical Structure of SARS-CoV-2,
external components, and viral single-stranded RNA.
Figure 2: the chart depicts the number of cases, deaths, and recoveries
from the SARS-COV1 during the time of infection (November 2002 through
July 2003).
Figure 3: the chart in the picture reveals the number of confirmed cases
in Yellow, deaths in Red, and the recovered from the infectious depicted
by Green color.
Figure 4: The chart expressing the number of confirmed cases of
SARS-COVID19 around the world in Yellow, the level of deaths in the Red,
and the Green column shows recovered number from the pandemic infectious
disease, according to the day of preparing research.
Figure 5: In the left shown the approximate average fatality rate among
SARS-COVID1 in Yellow with 10%, MERS in Red with
34%, and the ongoing SARS-COVID 19 in Blue color with the
average 5%.
Figure 6: From the charts that belong to each infectious we also can
conclude the comparison between then in the following table. it shows us
an incredible result.
Figure 7: the most dangerous rate of deaths recorded in Iran and Iraq.
fatality case rates in both countries are more than 4% Whereas The
fatality case rates in other countries are less than 1%, notably Qatar
recorded the lowest degree and located at the bottom of the level with
the fatality case rate 0.1%.
Figure 8: according to the population number Qatar has the highest level
of infection rate as shown by the Red column, and Iraq takes the lowest
level of infection illustrated in the green column. Others like Bahrain
with the rate of (0.018), Kuwait is 0.012, Oman in the level of (0.01),
KSA record is 0.006, UAE at the rate of (0.005), and Iran (0.002) by the
population number.
REFERENCES
1.Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. 2020. A
novel Coronavirus emerging in China-key questions for impact assessment
N Engl J Med 10.1056/NEJMp200092.1056/NEJMp20009299. doi:10
2. De Haan, C.A.; Rottier, P.J. Molecular interactions in the assembly
of coronaviruses. Adv Virus Res. 2005, 64, 165-230,
https://doi.org/10.1016/S0065-3527(05)64006-7.
3.Bárcena, M.; Oostergetel, G.T.; Bartelink, W.; Faas, F.G.A.; Verkleij,
A.; Rottier, P.J.M.; Koster, A.J.;
Bosch, B.J. Cryo-electron tomography of mouse hepatitis virus: Insights
into the structure of the
coronavirion. Proceedings of the National Academy of Sciences 2009, 106,
https://doi.org/10.1073/pnas.0805270106.
4.Roy, A.; Kucukural, A.; Zhang, Y. I-TASSER: a unified platform for
automated protein structure and
function prediction. Nature Protocols 2010, 5, 725-738,
https://doi.org/10.1038/nprot.2010.5.
5.Duquerroy, S.; Vigouroux, A.; Rottier, P.J.; Rey, F.A.; Bosch, B.J.
Central ions and lateral
asparagine/glutamine zippers stabilize the post-fusion hairpin
conformation of the SARS coronavirus spike glycoprotein. Virology 2005,
335, 276-285, https://doi.org/10.1016/j.virol.2005.02.022.
6.Monajjemi, M. Graphene/(h-BN)n/X-doped raphene as anode material in
lithium ion batteries (X = Li, Be, B AND N). Macedonian Journal of
Chemistry and Chemical Engineering 2017, 36, 101–118,
http://dx.doi.org/10.20450/mjcce.2017.1134.
7.Zhang, L.; Liu, Y. Potential interventions for novel coronavirus in
China: A systematic review. Journal of
Medical Virology 2020, 92, 479-490,
https://doi.org/10.1002/jmv.25707.
8.Sanders, J.M.; Monogue, M.L.; Jodlowski, T.Z.; Cutrell, J.B.
Pharmacologic Treatments for Coronavirus
Disease 2019 (COVID-19): A Review. JAMA 2020, 323, 1824-1836,
https://doi.org/10.1001/jama.2020.6019.
9.Grein, J.; Ohmagari, N.; Shin, D.; Diaz, G.; Asperges, E.; Castagna,
A.; Feldt, T.; Green, G.; Green, M.L.;
Lescure, F.-X.; Nicastri, E.; Oda, R.; Yo, K.; Quiros-Roldan, E.;
Studemeister, A.; Redinski, J.; Ahmed, S.;
Bernett, J.; Chelliah, D.; Chen, D.; Chihara, S.; Cohen, S.H.;
Cunningham, J.; D’Arminio Monforte, A.;
Ismail, S.; Kato, H.; Lapadula, G.; L’Her, E.; Maeno, T.; Majumder, S.;
Massari, M.; Mora-Rillo, M.; Mutoh,
Y.; Nguyen, D.; Verweij, E.; Zoufaly, A.; Osinusi, A.O.; DeZure, A.;
Zhao, Y.; Zhong, L.; Chokkalingam,
A.; Elboudwarej, E.; Telep, L.; Timbs, L.; Henne, I.; Sellers, S.; Cao,
H.; Tan, S.K.; Winterbourne, L.; Desai,
P.; Mera, R.; Gaggar, A.; Myers, R.P.; Brainard, D.M.; Childs, R.;
Flanigan, T. Compassionate Use of
Remdesivir for Patients with Severe Covid-19. New England Journal of
Medicine 2020.
10. Li, J.; Li, J.; Xie, X.; Cai, X.; Huang, J.; Tian, X.; Zhu, H. Game
consumption and the 2019 novel coronavirus. The Lancet Infectious
Diseases 2020, 20, 275-276,
https://doi.org/10.1016/S1473-3099(20)30063-3.
11.Sun, P.; Qie, S.; Liu, Z.; Ren, J.; Li, K.; Xi, J. Clinical
characteristics of hospitalized patients with SARS-
CoV-2 infection: A single arm meta-analysis. Journal of Medical Virology
2020, 92, 612-617, https://doi.org/10.1002/jmv.25735.
12.Poston, J.T.; Patel, B.K.; Davis, A.M. Management of Critically Ill
Adults With COVID-19. JAMA 2020, 323, 1839-1841,
https://doi.org/10.1001/jama.2020.4914
13.Lu H. 2020. Drug treatment options for the 2019-new coronavirus
(2019-nCoV). Biosci Trends 10.5582/bst.2020.01020. doi:
10.5582/bst.2020.01020.
14.Pillaiyar T, Meenakshisundaram S, Manickam M. 2020. Recent discovery
and development of inhibitors targeting coronaviruses. Drug Discov Today
S1359- 6446(20)30041-6. doi: 10.1016/j.drudis.2020.01.015.
15.Ng OW, Tan YJ. 2017. Understanding bat SARS-like coronaviruses for
the preparation of future corona virus outbreaks-Implications for
coronavirus vaccine development. Hum VaccinImmunother 13(1):186-189.
doi: 10.1080/21645515.2016.1228500.
16.Chen J. 2020. Pathogenicity and transmissibility of 2019-nCoV-A quick
overview and comparison with other emerging viruses. Microbes Infect
S1286-4579(20)30026-5. doi:10.1016/j.micinf.2020.01.004.
17. WHO. 2020. World Health Organization. Coronavirus disease 2019
(COVID-19) situation report, Situation report – 33 (22ndFebruary 2020).
Available online:
https://www.who.int/docs/default-source/coronaviruse/situationreports/20200222-sitrep-33-covid-19.pdf
(accessed on 25 February 2020).
18.Chen Y, Liu Q, Guo D. 2020. Emerging coronaviruses: genome structure,
replication, and pathogenesis J Med Virol 10.1002/jmv.25681.
doi:10.1002/jmv.25681.
19. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating
and Research Team. A novel coronavirus from patients with pneumonia in
China, 2019. N Engl J Med. 2020;382(8):727-733.
doi:10.1056/NEJMoa2001017
20. US Food and Drug Administration. Investigational COVID-19
Convalescent plasma: emergency INDs. Updated April 3, 2020. Accessed
21. World Health Organization. Clinical management of severe acute
respiratory infection when COVID-19 is suspected. Updated March 13,
2020. Accessed March 18, 2020. https://www.who.
int/publications-detail/clinical-management-ofsevere-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected
22. Arabi YM, Mandourah Y, Al-Hameed F, et al; Saudi Critical Care Trial
Group. Corticosteroid therapy for critically ill patients with Middle
East respiratory syndrome. Am J Respir Crit Care Med.
2018;197(6):757-767. doi:10.1164/rccm.201706- 1172OC
23. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19)
affect the eyes? A review of coronaviruses and ocular implications in
humans and animals. Ocul Immunol Inflamm 2020: 1-5
24. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of
SARS-CoVda target for vaccine and therapeutic development. Nat Rev
Microbiol 2009;7(3):226e36
25. ”UAE CORONAVIRUS
(COVID-19) UPDATES”. UAE’s national emergency crisis and disaster
management authority. Retrieved 15 April 2020.
26. Reynolds, Matt (4 March
2020). ”What is
coronavirus and how close is it to becoming a pandemic?”. Wired
UK. ISSN 1357-0978. Archived from
the original on 5 March 2020. Retrieved 5 March 2020
27.World Federation
Of Societies of Anaesthesiologists –
Coronavirus”. www.wfsahq.org . Archived from
the original on 12 March 2020. Retrieved 15 March 2020
28. ”Qatar
reports 951 new confirmed cases, 114 new recovered cases of
COVID-19”. www.iloveqatar.net. Retrieved 27 May 2020.